Your browser doesn't support javascript.
loading
A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.
Yu, Yong-feng; Chen, Zhi-wei; Zhou, Zhen; Song, Zheng-bo; Li, Zi-ming; Jian, Hong; Zhang, Yi-fei; Lu, Shun.
Affiliation
  • Yu YF; Shanghai Lung Tumor Clinical Medical Center, Chest Hospital affiliated to Shanghai Jiaotong University, Shanghai, China.
Chemotherapy ; 56(6): 472-7, 2010.
Article in En | MEDLINE | ID: mdl-21099219
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Non-Small-Cell Lung / Taxoids / Glutamates / Guanine / Lung Neoplasms / Neoplasm Recurrence, Local / Antineoplastic Agents Type of study: Health_economic_evaluation / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Chemotherapy Year: 2010 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Non-Small-Cell Lung / Taxoids / Glutamates / Guanine / Lung Neoplasms / Neoplasm Recurrence, Local / Antineoplastic Agents Type of study: Health_economic_evaluation / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Chemotherapy Year: 2010 Document type: Article Affiliation country: Country of publication: